Brii Biosciences Limited (2137.HK)
2137.HK Stock Price Chart
Explore Brii Biosciences Limited interactive price chart. Choose custom timeframes to analyze 2137.HK price movements and trends.
2137.HK Company Profile
Discover essential business fundamentals and corporate details for Brii Biosciences Limited (2137.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Jul 2021
Employees
98.00
Website
https://www.briibio.comCEO
Zhi Hong
Description
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
2137.HK Financial Timeline
Browse a chronological timeline of Brii Biosciences Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Mar 2026
Earnings released on 21 Aug 2025
EPS came in at -$0.22 surpassing the estimated -$0.30 by +25.93%.
Earnings released on 21 Mar 2025
EPS came in at -$0.33 falling short of the estimated -$0.24 by -35.36%, while revenue for the quarter reached $34.18M .
Earnings released on 19 Aug 2024
EPS came in at -$0.41 falling short of the estimated -$0.37 by -13.02%, while revenue for the quarter reached $23.79M .
Earnings released on 22 Mar 2024
EPS came in at $0.02 surpassing the estimated -$0.53 by +104.32%, while revenue for the quarter reached $17.96M .
Earnings released on 23 Aug 2023
EPS came in at -$0.28 falling short of the estimated -$0.26 by -8.58%, while revenue for the quarter reached $43.36M .
Earnings released on 24 Mar 2023
EPS came in at -$0.21 falling short of the estimated -$0.19 by -13.02%, while revenue for the quarter reached $107.51M , missing expectations by -77.46%.
Earnings released on 24 Aug 2022
EPS came in at -$0.56 surpassing the estimated -$0.73 by +22.77%, while revenue for the quarter reached $32.64M .
Earnings released on 23 Mar 2022
EPS came in at -$2.18 falling short of the estimated -$0.23 by -848.66%, while revenue for the quarter reached $57.40M .
Earnings released on 27 Aug 2021
EPS came in at -$17.84 falling short of the estimated $0.06 by -29.84K%, while revenue for the quarter reached $54.82M .
Earnings released on 9 Apr 2021
EPS came in at -$5.40 , while revenue for the quarter reached $72.58M .
2137.HK Stock Performance
Access detailed 2137.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.